News

Compugen Showcases COM701 Phase 1 Trials at International Forum

Compugen Showcases COM701 Phase 1 Trials at International Forum

Compugen Highlights COM701 Phase 1 Trials in Cancer Research

Compugen Ltd. (Nasdaq: CGEN) has recently announced its upcoming presentation of a pooled analysis of data from three Phase 1 trials involving COM701. This innovative research focuses on its application as both a monotherapy and a combination therapy for patients suffering from platinum-resistant ovarian cancer. The presentation is scheduled for a prominent international oncology conference, ensuring that the latest findings are shared with a global audience.

Significance of the ESMO Presentation

The presentation at the European Society for Medical Oncology (ESMO) event will be a significant opportunity to delve into the data surrounding COM701, which is a groundbreaking approach to cancer treatment. The trials investigate how COM701 can play a critical role in managing patients who have exhausted other therapeutic options. Given the severity of the condition, sharing these findings is vital for advancing treatment methodologies.

Key Details of the Poster Presentation

The title of the poster presentation is "COM701 in Ovarian Cancer: A Pooled Analysis of 3 Phase 1 Clinical Trials." It will be presented by Dr. Oladapo Yeku from Massachusetts General Hospital. Attendees can look forward to a thorough analysis that includes valuable insights from the data, aimed at fostering discussions on potential next steps in development.

About Compugen's Innovations

Compugen is a trailblazer in the field of therapeutic discovery, utilizing an advanced artificial intelligence/machine learning (AI/ML) platform to identify new drug targets and biological pathways that underpin cancer therapies. The firm is not just focusing on COM701 but has several promising candidates in various stages of clinical development, highlighting its commitment to pushing the boundaries of cancer treatment.

Among its leading candidates, COM902, designed to target the TIGIT pathway, showcases the company's dedication to exploring various immuno-oncology strategies aimed at enhancing patient outcomes. Moreover, Compugen is collaborating with AstraZeneca to develop a bispecific antibody that has shown significant potential in clinical trials, demonstrating the value of partnerships in accelerating drug development.

Future of Cancer Therapeutics

The work being presented at the ESMO conference underscores Steadfast’s mission of innovation in cancer care. By facilitating access to cutting-edge research findings, Compugen aims to foster an environment of collaboration and shared knowledge among healthcare professionals, researchers, and industry leaders. This approach is crucial for addressing the challenges that persist in oncology.

Furthermore, Compugen has various early-stage immuno-oncology programs in development. Its commitment to research stems from a deep-seated belief that understanding the unique mechanisms of tumor growth can lead to better immunotherapy solutions.

Commitment to Patients

As Compugen pushes the boundaries of what is possible in immunotherapy, the emphasis on patient-centered outcomes remains paramount. The company is dedicated to ensuring that its research not only advances scientific understanding but ultimately contributes to life-saving treatments for patients in dire need.

Company Information

Compugen is headquartered in Israel, with additional offices located in San Francisco, CA. Its dedication to finding therapeutic solutions through rigorous science is demonstrated by its active involvement in clinical trials and talks at major medical conferences like ESMO. By fostering innovation and collaboration, Compugen is positioned to play a key role in shaping the future landscape of cancer therapy.

Frequently Asked Questions

What is the focus of the COM701 trials?

The COM701 trials focus on evaluating its effectiveness as both a monotherapy and in combination with other therapies for patients with platinum-resistant ovarian cancer.

When and where will Compugen present its findings?

Compugen will present its findings at the ESMO 2025 conference, taking place in Berlin, Germany.

Who is presenting the research?

The research will be presented by Dr. Oladapo Yeku from Massachusetts General Hospital.

What other therapies is Compugen developing?

In addition to COM701, Compugen is developing COM902, a potential best-in-class antibody targeting the TIGIT pathway, among other immuno-oncology programs.

How does Compugen utilize AI in its research?

Compugen employs an AI/ML powered computational discovery platform to identify new drug targets, enhancing its ability to develop effective cancer immunotherapies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

PetSmart Charities Adds Strategy Role for Pet Families

Updated Category News Views 110

A pet bowl can become a crisis marker faster than people admit. Housing trouble, empty cupboards, a hurricane, or an unaffordable veterinary bill can turn a loved animal into one more impossible responsibility. That is the uncomfortable reality behind PetSmart Charities' decision to create a vice president of strategic programs and partnerships role and appoint Heather...

Continue Reading
Winter Leaks Can Lock In Tarrant Sewer Costs for 2027

Updated Category News Views 97

Silent toilet seepage has a nasty habit of turning winter into a twelve-month utility hangover. Tarrant County homeowners are heading into the period when some local cities use household water consumption to calculate residential sewer charges for the following year. That is not the sort of detail anybody enjoys thinking about during the holidays, but ignoring it can be...

Continue Reading
Gildan Lawsuit Puts Revenue Quality Under a Harsh Lens

Updated Category News Views 84

Inventory can hide a multitude of sins until somebody counts the boxes, and that is the ugly question hanging over Gildan Activewear. A federal securities class action alleges the company inflated reported sales and organic-growth figures by pushing excess product into wholesaler and distributor channels. Those are allegations, not findings of fact, and investors ought to...

Continue Reading
RMT’s 12.4% Discount Still Demands a Much Harder Look

Updated Category News Views 102

A $1.84 gap is staring RMT shareholders right in the face. As of October 31, 2026, Royce Micro-Cap Trust carried a net asset value of $14.82 per share while the market price sat at $12.98. That is roughly a 12.4% discount to NAV, and closed-end fund investors should never wave off a spread like that with a lazy shrug. It may be opportunity. It may also be the market...

Continue Reading
Mace Consult Bets on Sawaya for Americas Expansion

Updated Category News Views 151

Concrete, tunnel bores, and data-center campuses rarely wait politely for a leadership transition. Mace Consult has named Mario Sawaya president of its Americas business, and the hire reads less like ceremonial executive shuffling than a deliberate move toward the thickest part of the capital-spending map. Sawaya brings more than 20 years of experience leading...

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 84

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading
Software-Defined Cars Put $310 Billion in Play by 2035

Updated Category News Views 111

Cars are becoming rolling computers, and that changes who gets paid. Market Growth Reports projects the software-defined vehicle market will rise from $56.94 billion to $310.46 billion by 2035, a 20.74% compound annual growth rate. That is a loud number, no question. Still, investors ought to treat any long-range market forecast like a map, not a mortgage deed. The...

Continue Reading
Oman’s Dhofar II Wind Deal Clears Financing Hurdle

Updated Category News Views 95

Dhofar’s next wind farm has crossed the line that matters: financial close. That is less glamorous than turbines spinning against an Omani skyline, but it is the point where a project stops being an attractive deck and becomes a real contractual obligation. Sembcorp Utilities, alongside OQ Alternative Energy through Naseem Dhofar SAOC, has brought the 125-megawatt...

Continue Reading
RBC Signals Gets $10 Million to Push Space Infrastructure

Updated Category News Views 135

Ground stations are the unglamorous plumbing of the space economy, and somebody finally put fresh capital behind the wrench. RBC Signals says it has received a $10 million strategic growth investment led by Washington Harbour Partners, aimed at enlarging its government-services operation and pushing several newer space-connectivity tools toward commercial use. This is a...

Continue Reading
Vanguard's Digital Win Matters More Than a Trophy

Updated Category News Views 182

A wealth manager’s website rarely earns applause, but a bad one can sure as hell lose trust fast. Vanguard’s move to No. 1 from No. 3 in the 2025 ranking for advised-investor website satisfaction is worth noticing because it hits the unglamorous part of wealth management that clients actually live with: checking accounts, understanding a plan, moving cash, and...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative AI Tools Revolutionizing Family Medicine Screening

Updated Category News Views 120

Innovative AI Tools Revolutionizing Family Medicine Screening Recent studies illustrate the integration of AI in detecting health issues within family medicine Research published in Annals of Family Medicine delves into how artificial intelligence and digital applications such as tablets are enhancing the detection of significant health conditions like dementia, heart...

Continue Reading
Infortar's Strategic Share Buyback on Nasdaq Tallinn

Updated Category News Views 168

Infortar's Share Buyback Strategy Aktsiaselts Infortar has taken a strategic step by acquiring its own shares on the Nasdaq Tallinn Stock Exchange during the early November period. This initiative reflects the company’s commitment to enhancing shareholder value and maintaining a robust market presence. Details of the Share Acquisition During the acquisition phase from...

Continue Reading
Garmin Ltd. Announces Upcoming Earnings Call for Investors

Updated Category News Views 41

Garmin Ltd. Schedules Third Quarter Earnings Call Garmin Ltd. (NYSE: GRMN) is preparing for its third quarter earnings conference call, inviting all shareholders and interested parties to join. The call is an important event where executives will discuss recent business performance and future strategies. It will take place on a Wednesday at 10:30 a.m. EDT, coinciding with...

Continue Reading
BMC Medical Co., Ltd. Celebrates New France Office Opening

Updated Category News Views 152

Exciting Times for BMC Medical Co., Ltd. with New Office Opening BMC Medical Co., Ltd. has recently marked an important milestone with the launch of its new office. This occasion not only establishes a foothold in the local area but also demonstrates the company's commitment to improving healthcare services throughout Europe. A Grand Opening Ceremony Celebrating Growth...

Continue Reading
TGH Burn Center Enhances Care Through TECO Partnership

Updated Category News Views 202

Transforming Burn Care at TGH Burn Center The TGH Burn Center, previously known as Tampa General Hospital's Burn Center, has entered into an exciting partnership with TECO that aims to significantly enhance patient care. This collaboration focuses on innovative treatment and state-of-the-art technology to ensure that those suffering from burn injuries receive the best...

Continue Reading